Trials / Completed
CompletedNCT06215911
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 557 (actual)
- Sponsor
- Cardurion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tovinontrine (CRD-750) | Tablets administered orally |
| DRUG | Placebo | Tablets administered orally |
Timeline
- Start date
- 2024-02-13
- Primary completion
- 2025-10-10
- Completion
- 2025-10-10
- First posted
- 2024-01-22
- Last updated
- 2025-11-17
Locations
139 sites across 19 countries: United States, Australia, Belgium, Bulgaria, Canada, Czechia, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Slovakia, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06215911. Inclusion in this directory is not an endorsement.